Although OM has been developed as a heart failure drug, the expression of cardiac myosin (Myh7 or β-MHC) in both heart and slow skeletal muscle[21], predicts that OM is effective in slow skeletal muscle as well, and the findings of the present study clearly bear this out. Here, MYH7 is linked to ocular melanoma.